Clinical Trial Update: Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

A Phase 2 trial evaluating the combination of trastuzumab, tucatinib, and vinorelbine in HER2-positive locally advanced or metastatic breast cancer has been ter…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Trastuzumab (trastuzumab)
• Tukysa (tucatinib)
• Vinorelbine (Vinorelbine)

Snippet

Sponsor: Spanish Breast Cancer Research Group | Conditions: HER2-positive Metastatic Breast Cancer, Locally Advanced HER2 Positive Breast Carcinoma | Phase 2 | Status: TERMINATED